Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Analysis of informed consent forms of patients undergoing cancer genetic testing in the era of next-generation sequencing
Authors:ID Kerševan, Tina (Author)
ID Kogovšek, Tina (Author)
ID Blatnik, Ana (Author)
ID Krajc, Mateja (Author)
Files:.pdf PDF - Presentation file, download (1,29 MB)
MD5: 4B7A9287B2FFDE537FBDA4B59B06C96E
 
URL URL - Source URL, visit https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-025-00309-8
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:The Department of Clinical Cancer Genetics at the Institute of Oncology Ljubljana offers genetic counselling and testing to cancer patients and their relatives. Before undergoing genetic testing, patients sign the informed consent form. In addition to giving consent for collection of biological material and genetic testing, patients decide about storage of biological material and participation in international databases. Furthermore, patients decide whether the information regarding their test results may be revealed to their blood relatives and whether they want to be informed about secondary findings. Methods Using the signed consent forms, we investigated the effect of selected factors on patients’ decisions. Using different statistical methods, we tried to determine the proportion of patients who opted for different items and the effect of gender, age and cancer diagnoses on their decisions. Results Nearly all (99.6%) patients, regardless of gender, age, and presence of oncological diagnosis, consented to the storage of their biological material, 98.4% of patients, regardless of gender, age, and presence of oncological diagnosis, wanted to be included in international databases in a pseudo-anonymised form, 98.8% of patients, irrespective of gender, age, and presence of oncological diagnosis, allowed blood relatives to see their results, and 98.4% of patients, irrespective of gender, age and presence of oncological diagnosis, wanted to know whether secondary findings were detected when genetic analysis of their biological material was performed. Men are, on average, more likely to consent but the difference between genders is not statistically significant. Patients without oncological disease were more likely to agree to be included in international databases than patients with a confirmed oncological diagnosis. Conclusions Our results show that the vast majority of patients were in favour of the options they were offered. Most importantly, the majority of them allow their genetic test results be revealed to their blood relatives when needed and would participate in international databases. Research in rare diseases, including rare cancer genetic predisposition syndromes, is crucial for optimal diagnostic, prevention and treatment options for patients with rare genetic disorders. The results are also important for refining the approach to pre-and post-test cancer genetic counselling.
Keywords:informed consent, genetic counselling, genetic testing
Publication status:Published
Publication version:Version of Record
Submitted for review:15.11.2024
Article acceptance date:13.02.2025
Publication date:21.02.2025
Publisher:BioMed Central Ltd (Springer Nature)
Year of publishing:2025
Number of pages:9 str.
Numbering:Vol. 23
PID:20.500.12556/DiRROS-23999 New window
UDC:616-07
ISSN on article:1897-4287
DOI:10.1186/s13053-025-00309-8 New window
COBISS.SI-ID:227017219 New window
Copyright:by Authors
Note:Nasl. z nasl. zaslona; Opis vira z dne 8. 10. 2025;
Publication date in DiRROS:19.11.2025
Views:111
Downloads:51
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Hereditary Cancer in Clinical Practice
Shortened title:Hered. Cancer Clin. Pract.
Publisher:Termedia
ISSN:1897-4287
COBISS.SI-ID:523112217 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0289-2019
Name:Značilnosti malignih neoplazem, pomembne za diagnozo ter napoved poteka bolezni in izida zdravljenja

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:informirano soglasje, genetsko svetovanje, genetsko testiranje


Back